EWEdwards Lifesciences
Price
+14%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, no red flags, price roughly fair, growth steady, the market undecided.
Edwards Lifesciences Corporation is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence, and meaningful partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Edwards Lifesciences has been a leader in our field for over six decades.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Edwards Lifesciences (EW) reported revenue of $1.74B in Q2 2026 (quarter ended Jun 30, 2026), up 14% from the same quarter a year earlier. That came with a gross margin of 77% and net income of $241M (14% of revenue). For the full year FY2025, revenue was $6.07B (+12% year on year) and net income $1.07B. Its largest product in Q2 2026 was Transcatheter Aortic Valve Replacement at $1.26B, 72% of the disclosed total, well ahead of Surgical at 16%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 28, 2026The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, of his decision to retire from the Company by mid-year 2027.Director or officer change · Form 8-K
- Jul 23, 2026Edwards Lifesciences Corporation.Earnings release · press release
- May 8, 2026Approval of the Amended and Restated Long-Term Stock Incentive Compensation Program At the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Edwards Lifesciences Corporation, a Delaware Corporation (the “Company”), the Company’s stockholders approved the amendment and restatement of the Company’s Long-Term …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $1.74BThe company’s own SEC segment disclosure.
- Transcatheter Aortic Valve Replacement$1.26B72%
- Surgical$284.1M16%
- Transcatheter Mitral And Tricuspid Therapies$198.6M11%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Devices
The closest names by size in the same industry